Comparison of three different Drugs in three different groups and noting down for etomidate induced myoclonus

Comparison of etomidate priming vs intravenous lignocaine vs placebo for reducing etomidate induced myoclonus: a randomised controlled - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/083733

Enrollment

150

Registered

2025-03-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Placebo group: Etomidate -0.3mg/kg with placebo (normal saline)-bolus intravenously Control Intervention1: Lignocaine group: Etomidate 0.3mg/kg with intravenous lignocaine 1.5mg/kg as a

Eligibility

Inclusion criteria

Inclusion criteria: ASA 1-2

Exclusion criteria

Exclusion criteria: Patient refusal Inability to give consent to study Coagulopathy,sepsis,hepatic or renal failure Patient on steroid Cardiac disorder Renal disorder/endocrine disorders

Design outcomes

Primary

Measure	Time frame
Incidence of myoclonusTimepoint: Incidence of myoclonus after induction,0min, 1min,2 min	—

Secondary

Measure	Time frame
Time of onset, induction dose, Loc time & loc doseTimepoint: after induction -0min,1min,2min	—

Countries

India

Contacts

Public ContactDr.Keerthana

Sri Ramachandra medical college and research hospital

vrajesh.kodali@gmail.com944230150

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026